Zhu Yuwen, Pan Yanbin, Fan Lichao, Zou Meng, Liu Yingjie, Hu Jiayi, Xia Shijun, Li Yue, Dai Ruijie, Wu Wenjiang
Department of Anorectal Surgery, Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China.
Department of Anorectal Surgery, Shenzhen Traditional Chinese Medicine Anorectal Hospital, Shenzhen, China.
Transl Cancer Res. 2024 Aug 31;13(8):3960-3973. doi: 10.21037/tcr-24-274. Epub 2024 Aug 27.
The incidence of inflammatory bowel disease (IBD) is increasing every year and is characterized by a prolonged course, frequent relapses, difficulty in curing, and a lack of more efficacious therapeutic biomarkers. The aim of this study was to find key core genes as therapeutic biomarkers for IBD.
GSE75214 in Gene Expression Omnibus (GEO) was used as the experimental set. The genes in the top 25% of standard deviation of all samples in the experimental set were subjected to systematic weighted gene co-expression network analysis (WGCNA) to find candidate genes. Then, least absolute shrinkage and selection operator (LASSO) logistic regression was used to further screen the central genes. Finally, the validity of hub genes was verified on GEO dataset GSE179285 using "BiocManager" R package.
Twelve well-preserved modules were identified in the experimental set using the WGCNA method. Among them, five modules significantly associated with IBD were screened as clinically significant modules, and four candidate genes were screened from these five modules. Then , , and were screened as hub genes. These hub genes successfully distinguished tumor samples from healthy tissues by artificial neural network algorithm in an independent test set with an area under the working characteristic curve of 0.946 for the subjects.
IBD differentially expressed gene (DEGs) are involved in immunoregulatory processes. , , and , as core genes of IBD, have the potential to be therapeutic targets for patients with IBD, and our findings may provide a new outlook on the future treatment of IBD.
炎症性肠病(IBD)的发病率逐年上升,其病程长、复发频繁、难以治愈,且缺乏更有效的治疗生物标志物。本研究旨在寻找关键核心基因作为IBD的治疗生物标志物。
将基因表达综合数据库(GEO)中的GSE75214用作实验组。对实验组中所有样本标准差前25%的基因进行系统加权基因共表达网络分析(WGCNA)以寻找候选基因。然后,使用最小绝对收缩和选择算子(LASSO)逻辑回归进一步筛选核心基因。最后,使用“BiocManager”R包在GEO数据集GSE179285上验证枢纽基因的有效性。
使用WGCNA方法在实验组中鉴定出12个保存良好的模块。其中,筛选出与IBD显著相关的5个模块作为具有临床意义的模块,并从这5个模块中筛选出4个候选基因。然后,筛选出 、 和 作为枢纽基因。在独立测试集中,这些枢纽基因通过人工神经网络算法成功区分肿瘤样本与健康组织,受试者工作特征曲线下面积为0.946。
IBD差异表达基因(DEGs)参与免疫调节过程。 、 和 作为IBD的核心基因,有可能成为IBD患者的治疗靶点,我们的研究结果可能为IBD的未来治疗提供新的前景。